Efficacy and Safety of Anlotinib Plus EGFR-TKIs in Slowly or Locally Progressing NSCLC after Adjuvant Therapy with EGFR-TKIs

被引：0
|
作者：
Ye, J. [1 ]
Liu, J. [1 ]
Yang, Y. [1 ]
Lv, W. [1 ]
Xu, W. [2 ]
Xia, P. [1 ]
Wang, L. [1 ]
Zhu, L. [1 ]
Hu, J. [1 ,3 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Hangzhou, Peoples R China
[2] Sanmen Peoples Hosp, Taizhou, Peoples R China
[3] Key Lab Clin Evaluat Technol Med Device Zhejiang, Hangzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Anlotinib; NSCLC; EGFR-TKIs;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.07E.04
引用
收藏
页码：S554 / S554
页数：1
相关论文
共 50 条
  • [31] The efficacy of different immunotherapy strategies to NSCLC patients after resistance to EGFR-TKIs: A retrospective study
    Huang, Jiuyan
    Wei, Chunhua
    Wang, Huijuan
    ASIAN JOURNAL OF SURGERY, 2024, 47 (11) : 5078 - 5079
  • [32] Efficacy of EGFR-TKIs for EGFR Mutant NSCLC Patients with Central Nervous System Metastases: A Retrospective Analysis
    Koyama, K.
    Saida, Y.
    Abe, T.
    Satokata, M.
    Mishina, Y.
    Sato, K.
    Shoji, S.
    Tanaka, T.
    Nozaki, K.
    Ichikawa, K.
    Miyabayashi, T.
    Ota, T.
    Fujimori, F.
    Ito, R.
    Kondo, R.
    Hiura, T.
    Okajima, M.
    Miura, S.
    Watanabe, S.
    Matsumoto, N.
    Tanaka, H.
    Kikuchi, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2132 - S2132
  • [33] Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study
    Huang, Chu-ying
    Wang, Li
    Feng, Cheng-jun
    Yu, Ping
    Cai, Xiao-hong
    Yao, Wen-xiu
    Xu, Yong
    Liu, Xiao-ke
    Zhu, Wen-jiang
    Wang, Yan
    Zhou, Jin
    Lu, You
    Wang, Yong-sheng
    ONCOTARGET, 2016, 7 (41): : 66480 - 66490
  • [34] The role of EGFR-TKIs as adjuvant therapy in EGFR mutation-positive early-stage NSCLC: A meta-analysis
    Lin, Chutong
    Hu, Fengling
    Chu, Hongling
    Ren, Peng
    Ma, Shanwu
    Wang, Jingdi
    Bai, Jie
    Han, Xuan
    Ma, Shaohua
    THORACIC CANCER, 2021, 12 (07) : 1084 - 1095
  • [35] Association between clinical outcome of first EGFR-TKIs and T790M mutation in NSCLC patients harboring EGFR mutation with acquired resistance to EGFR-TKIs
    Oya, Y.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S622 - S622
  • [36] Bisphosphonates enhance effect of EGFR-TKIs in NSCLC patients with EGFR mutation and bone metastases
    Jiang, T.
    Zhou, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [37] Bisphosphonates Enhance Effect of EGFR-TKIs in NSCLC Patients with EGFR Mutation and Bone Metastases
    Jiang, Tao
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1236 - S1236
  • [38] An EGFR KDD Data in the Chinese NSCLC Population and the Response to EGFR-TKIs: A Multicenter Study
    Wang, W.
    Xu, C.
    Zhu, Y.
    Fang, M.
    Zhuang, W.
    Chen, Y.
    Chen, G.
    Lv, T.
    Song, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1081 - S1081
  • [39] Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients
    Xiong, Liwen
    Cui, Shaohua
    Ding, Jingyan
    Sun, Yun
    Zhang, Longfu
    Zhao, Yizhuo
    Gu, Aiqin
    Chu, Tianqing
    Wang, Huimin
    Zhong, Hua
    Ye, Xin
    Gu, Yi
    Zhang, Xin
    Hu, Min
    Jiang, Liyan
    ONCOTARGET, 2017, 8 (38) : 63846 - 63856
  • [40] EGFR-TKIs plus local therapy demonstrated survival benefit than TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases
    Jiang, T.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S74 - S74
12345